---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070305"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T18:37:17.760304+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports Q1 2025 net loss of $10.6M; cash runway extended to 2028

## Summary
- Net loss of $10.6M vs $16.6M in Q1 2024; R&D expenses down to $7.7M from $14.7M.
- Cash and investments of $78.5M at March 31, 2025; operating runway now projected into 2028.
- Initiated Phase 1 first-in-human study of AN2-502998 for chronic Chagas disease; expected completion in H2 2025.
- Plans to initiate Phase 2 study of epetraborole in melioidosis; advancing epetraborole for NTM lung disease non-dilutive.
- Oncology pipeline advancing; first compound(s) expected to enter development in 2025 within current cash runway.

## SEC filing metadata
- accession: 0000950170-25-070305
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017025070305/0000950170-25-070305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017025070305/antx-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070305
- JSON: https://secwatch.observer/filing/0000950170-25-070305.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070305.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.